Safe Step Act
Summary
The Safe Step Act (S.2903) remains in early Senate committee stage after a March 2026 hearing. It imposes an administrative mandate on payers and PBMs but authorizes zero spending. Near-zero probability of near-term enactment. Managed care stocks $UNH, $CI, $CVS have rallied 9-40% over 30 days on non-legislative drivers; this bill is not a factor in their current valuations.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.The Safe Step Act (S.2903) mandates payer/PBM step therapy exceptions but authorizes zero federal spending — purely a compliance cost regulation, not a spending bill.
- 2.Still in early committee stage after one hearing; no floor vote scheduled; low probability of enactment in this Congress despite bipartisan cosponsors.
- 3.Managed care stocks $UNH, $CI, $CVS are rallying on powerful non-legislative drivers (30-day gains of 9-40%) — attributing any of this to the Safe Step Act would be incorrect.
Market Implications
No actionable market implications at this time. The Safe Step Act is a procedural bill with zero funding and an uncertain legislative path. The 30-day rally in managed care stocks (UNH +36%, CI +9%, CVS +16%, HUM +39%) is driven by Q1 earnings and Medicare Advantage rate tailwinds, not legislative risk. Investors should monitor committee markup announcements but do not adjust positions based on this bill's current status. If the bill advances to a floor vote, managed care margins face a ~1-3% headwind from administrative compliance costs, but this is a watch-and-wait scenario only.
Full Analysis
What happened: Senator Murkowski (R-AK) introduced S.2903, the Safe Step Act, on September 18, 2025. The bill was read twice and referred to the Committee on Health, Education, Labor, and Pensions. A hearing was held on March 19, 2026. The bill has 43 cosponsors (bipartisan) and a companion bill in the House (HR5509). Despite this support, it remains in early-stage committee process with no floor vote scheduled.
The money trail: This bill authorizes ZERO federal spending. It is a regulatory mandate on private health plans and insurers, not an appropriations bill. The financial impact is purely a compliance cost shift. Insurers and PBMs must implement an exceptions process at their own administrative expense. There is no government funding to offset these costs. This distinguishes the Safe Step Act from authorization bills that set spending ceilings — here, the mandate is unaccompanied by any federal dollars.
Structural winners and losers: Pharmaceutical companies that face step therapy barriers for their drugs are the clearest structural beneficiaries — brands with narrow step therapy or fail-first protocols get an easier path to prescribing if the exception process is used by physicians. However, no pharma tickers are included in this analysis because the link from legislative text to specific company revenue is too diffuse and uncertain at this early stage. Payers and PBMs ( OptumRx, $CI Evernorth/Caremark, Caremark) face modest administrative costs and potential loss of formulary control. The magnitude is small relative to their overall revenue — compliance costs for exception processing are trivial compared to these companies' hundreds of billions in annual revenue.
Real market data context: UnitedHealth is at $368.12, up 36.04% in 30 days. Cigna ($CI) is at $291.96, up 9.45%. CVS is at $83.58, up 16.37%. These moves are driven by Q1 earnings, sector-wide managed care tailwinds following Medicare Advantage rate finalization, and broader market dynamics — not by a bill that had a single hearing and has no clear path to passage.
Timeline: The bill has cleared only one procedural step after introduction (a hearing). Next steps: committee markup (not scheduled), floor vote in Senate (months away at best), House passage of companion bill (HR5509 referred to committee but no hearing yet), conference committee, and presidential signature. Realistically, this bill has a low probability of enactment in the 119th Congress given the crowded legislative calendar and the absence of committee chair leadership (Senator Murkowski is a senior member but not chair of HELP). A more plausible timeline is the 120th Congress (2027-2029) if momentum builds.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
No confirming evidence found yet from contracts, insider trades, or congressional activity
What the bill does
Mandate for insurers and PBMs to implement an exceptions process for step therapy protocols
Who must act
The Cigna Group's health insurance and PBM operations (Evernorth/Caremark)
What happens
Requires administrative process changes and potential increase in prescription drug claims if exceptions are granted for non-preferred drugs
Stock impact
Cigna's PBM (Evernorth/Caremark) could see a modest increase in operational costs for exception processing and potentially higher drug spend if exception approvals bypass step therapy. The 30-day change of +9.45% to $291.96 is driven by broader sector tailwinds, not this specific bill.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
TRIWEST HEALTHCARE ALLIANCE CORP: $820M Department of Veterans Affairs Contract
Veteran Caregiver Reeducation, Reemployment, and Retirement Act
Association Health Plans Act
Medicare for All Act
Veterans’ ACCESS Act of 2025
Protecting Health Care and Lowering Costs Act
Living Donor Protection Act of 2025
To amend the Employee Retirement Income Security Act of 1974 to ensure that pharmacy benefit managers are considered fiduciaries, and for other purposes.
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Delivering Gold Standard Childhood Vaccine Recommendations for Americans
This executive order directs HHS to establish a 'Gold Standard' childhood vaccine schedule with fewer recommended vaccines than current CDC guidelines, mandates that MMR be administered as three separate single-disease shots when domestically available, and instructs the DOJ to challenge state vaccine mandates that do not provide religious or medical exemptions. It also orders HHS to develop alternative adjuvants to aluminum and improve vaccine safety monitoring, while preserving access to existing vaccines.
Continuing to Protect the Meaning and Value of American Citizenship
This executive order directs federal agencies, including State, Justice, Homeland Security, and Social Security, to deny U.S. citizenship documentation to children born in the U.S. whose parents include alien enemies, foreign government employees, or those involved in commercial birth tourism or surrogacy, or who are born in territories without statutory citizenship. It implements a narrow interpretation of the Fourteenth Amendment following the Supreme Court's decision in Trump v. Barbara, effectively restricting birthright citizenship for specific categories of non-citizen parents.
Ending Birth Tourism
This executive order directs the Secretaries of State and Homeland Security to prevent foreign nationals from entering the U.S. on nonimmigrant visas for the purpose of giving birth (birth tourism), including revoking visas, barring entry, and taking action against facilitators. It defines birth tourism as entry via nonimmigrant visa for childbirth and allows humanitarian or national interest exemptions.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →